AVITA Therapeutics Inc (ASX:AVH) disclosed its annual report for FY20 (year ended 30 June 2020).
- Revenue of the RECELL System totaled US$14.3 million for the financial year 2020, an increase of 161% (or US$8.8 million) over the US$5.5 million for FY19.
- During the period, US sales totaled US$13.8 million compared to US$4.4 million in the prior year.
- AVITA had cash and restricted cash of US$73.8 million as of 30 June 2020 compared to US$20.4 million as of 30 June 2019.
Post announcement on 28 August 2020, AVH share price was trading at A$6.660 up by 8.293% at AEST 12:03 AM.